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ABSTRACT 
Host-parasite interaction in men with febrile urinary tract infection 
Peter Ulleiyd, Department of Infectious Diseases, Institute of Internal Medicine, 
Göteborg University, S-416 85 Göteborg, Sweden. 
e-mail: peter.ulleiyd@medfak.gu.se 
In a retrospective study, Escherichia coli isolates from 88 men with symptomatic 
urinary tract infection (UTI) were analysed. A wide array of 0:K:H serotypes 
commonly associated with acute pyelonephritis in women were identified. There 
was a higher frequency of haemolytic strains among patients with febrile UTI (74%) 
and a lower frequency of P fimbriated (51%) and aerobactin-positive strains (46%) 
than previously encountered in women with uncomplicated acute pyelonephritis. 
Different clinical aspects of febrile UTI were prospectively studied in 86 men. 
Although only nine (12%) of 76 patients had a tender prostate on digital rectal 
examination, the initial serum prostate-specific antigen (PSA) was elevated in 58 
(83%) men. Among 55 men who had PSA analysed twice, 51 (93%) showed a 
reduction of PSA by > 25 % after three months. The median prostate volume was 
reduced from 49 mL to 35 mL. The results indicate that the prostate is frequently 
engaged by the infection in men with febrile UTI. The slow decline of PSA levels in 
some patients after treatment should be considered when PSA is used for the 
detection of prostate cancer. 
Radiological examination of the upper urinary tract in 83 patients revealed 
abnormal findings in 19 (23%) patients. Lower urinary tract investigation disclosed 
abnormal findings in 35 men. Surgically correctable disorders were found in 20 
patients, 15 of whom had previously unrecognised abnormalities. All patients 
requiring surgery were identified either by a history of voiding difficulties, acute 
urinary retention, the presence of microscopic haematuria at short-term follow-up, 
or early recurrent symptomatic UTI. Accordingly, routine imaging of the upper 
urinary tract seems dispensable in men with febrile UTI. 
Seventy-two patients were randomised to treatment with ciprofloxacin 500 mg 
b.i.d. for 2 or 4 weeks, respectively. The outcome was excellent in both groups. 
There was no significant difference in short-term bacteriological cure rate between 
the groups (89% vs 97%), nor in cumulative bacteriological cure rate after 1-year's 
follow-up (59% vs 76%). The cumulative clinical cure rate after one year was 72% 
and 82%, respectively. A 2-week course of ciprofloxacin 500 mg b.i.d. seems 
adequate for treatment of men with febrile UTI. 
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ABBREVIATIONS 
ABU asymptomatic bacteriuria 
BPH benign prostatic hyperplasia 
CFU colony-forming units 
CRP C-reactive protein 
ESR erythrocyte sedimentation rate 
H antigen flagellar antigen 
K antigen capsular antigen 
MSU midstream urine 
O antigen lipopolysaccharide somatic antigen 
PSA prostate-specific antigen 
TRUS transrectal ultrasound of the prostate 
TURP transurethral resection of the prostate 
UTI urinary tract infection(s) 
WBC white blood cell count 
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INTRODUCTION 
Urinary tract infections (UTI) are one of the most common infectious diseases 
encountered in primary care practice, hospitals and extended care facilities [1], 
The incidence of UTI varies with sex, age and predisposing conditions. UTI more 
frequently afflict women than men at all ages, except in the first year of life [2, 3]. 
Although the prevalence of bacteriuria and incidence of symptomatic infections 
increase in elderly men because of urological abnormalities and instrumentation, 
UTI is veiy uncommon in otherwise healthy young and middle-aged men [1], An 
estimated annual incidence of 6-8 UTI per 10000 men aged 21 to 50 was reported 
in a study from Norway [4], 
UTI is the result of interactions between bacterial virulence and host defence 
mechanisms at several levels [5]. In individuals with normal urinary tracts, to 
cause infection, bacteria have to be equipped with certain properties, i.e. virulence 
factors, making it possible to overcome host defences [6]. Such infections are 
designated as uncomplicated and typically occur in young, healthy, non-pregnant 
females. 
The term complicated UTI is used for patients who have underlying functional or 
structural abnormalities of the urinary tract which predispose to infection by 
impeding urine flow [7, 8]. Patients with complicated UTI tend to be infected with a 
broader spectrum of less virulent bacteria, run a high risk of bacteraemia, have 
antibiotic treatment failures, and are prone to recurrent infections [1, 9]. 
The natural histoiy of UTI, pathogenetic mechanisms, risk factors, as well as the 
need for urinaiy tract investigation and follow-up have been extensively studied in 
women and children [1]. Also, numerous, controlled treatment trials have provided 
information about the proper choice of antimicrobial agents and duration of 
treatment of symptomatic UTI in women [10, 11]. 
In men, however, these issues have received little attention. There is an apparent 
lack of s tudies of well-defined groups of men with specified types of UTI [ 12-14]. 
One obvious reason for this is that UTI is uncommon in adult men. 
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Escherichia coli is the most common cause of UTI in women and children, 
accounting for more than 80 per cent of the episodes, especially in those with 
uncomplicated infections [15]. Other bacterial species have been proposed to play a 
more important role in men but patients studied have often been compromised by 
urological abnormalities [16, 17]. As in young women, however, symptomatic UTI 
in young healthy men with normal urinaiy tracts seem to be caused primarily by 
E. coli [18]. 
The faecal flora constitutes a reservoir for potential uropathogens. Successful 
invasion of the lower urinaiy tract in women is preceded by colonisation of the 
periurethral area and is determined by bacterial virulence and the integrity of host 
defence mechanisms. Uropathogenic E. coli possess an array of virulence 
properties that participate at different stages of the infectious process. Adhesins 
mediating attachment to epithelial cells seem to play an important role in 
colonisation of mucosal surfaces and the ascent of bacteria into the urinaiy tract 
[5], 
E. coli isolated from women with uncomplicated acute pyelonephritis more often 
belong to certain 0:K:H serotypes and more frequently express virulence properties 
like P fimbriae, haemolysin and aerobactin than E. coli strains in the faecal flora or 
those isolated from patients with asymptomatic bacteriuria (ABU) o r acute cystitis 
[19]. However, when host defences are compromised, as in patients with functional 
or structural abnormalities of the urinaiy tract, infections are often caused by a 
diversity of less virulent E. coli strains [20]. 
Only a small number of E. coli strains from men with various types of UTI have 
been characterised as regards serotype and virulence properties [21, 22]. As in 
women and children, bacteria causing UTI in men are thought to reach the urinaiy 
tract by the ascending route. The relatively long distance between the urethral 
meatus and the perianal region, the length of the male urethra and the bactericidal 
activity of prostatic fluid make it difficult for microorganisms to gain access to the 
urinary tract in men. 
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Residual urine secondary to intravesical obstruction due to prostatic enlargement 
has often been suggested as an important factor for the increased incidence of 
symptomatic UTI in elderly men but compelling evidence is lacking [23, 24]. 
It is unknown to what extent the prostate is coinfected in men with UTI. Recurrent 
UTI, however, is often caused by the same bacterial strain as the previous 
infections, indicating a chronic focus of infection within the urinary tract. In the 
absence of concretions, exacerbation of chronic bacterial prostatitis has been 
suggested as a cause of such recurrences [25-27]. Retrograde transport of bacteria 
from the urethra into the prostate, facilitated by reflux of urine into the prostatic 
ducts, has been proposed as a possible mechanism by which bacteria reach the 
prostate gland [28]. 
It is generally agreed that men with UTI warrant a thorough urological evaluation 
to identify predisposing structural or functional abnormalities [29-31]. This 
recommendation is based on the assumption that such disorders are common in 
male UTI, but most studies were carried out in highly selected patients in various 
clinical settings. It has recently been suggested, however, that imaging studies of 
the upper urinary tract should primarily be reserved for men with febrile UTI, those 
who fail to respond to appropriate antibiotic treatment and those prone to 
recurrent infections [32]. 
Few studies have focused on appropriate treatment of UTI in men. Published 
studies have included patients with a history of recurrent UTI and ABU [33, 34] or 
miscellaneous types of infections [27, 35], Treatment courses of 6-12 weeks have 
resulted in higher bacteriological cure rates than short-term treatment for 10-14 
days but the follow-up periods have usually been short. 
This study was initiated to investigate various aspects of the host-parasite 
relationship in men with febrile UTI. It has been a multidisciplinaiy project 
performed in close collaboration between bacteriologists, urologists and infectious 
disease specialists. 
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AIMS OF THE STUDY 
• To characterise 0:K:H serotypes and phenotypic virulence properties of E. coli in 
relation to the host response in men with symptomatic UTI. 
• To study the frequency of prostatic involvement in men with febrile UTI. 
• To investigate the occurrence and clinical relevance of urological abnormalities 
in men with febrile UTI. 
• To compare the bacteriological and clinical efficacy of ciprofloxacin 500 mg 
twice daily for two and four weeks in a prospective, randomised treatment trial 
of men with febrile UTI. 
• To determine the frequency and characteristics of recurrent UTI during one 
year's follow-up after treatment of men with febrile UTI. 
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PATIENTS 
Retrospective study (I) 
Eighty-eight men who presented at the Department of Infectious Diseases, 
Sahlgrenska University Hospital/Östra, Göteborg between 1983 and 1992 with 
community-acquired symptomatic UTI due to E. coli were enrolled in the study. 
Most patients participated in controlled, comparative treatment trials of 
symptomatic UTI [36-38]. Clinical and laboratory data were obtained from case-
record forms and the medical records of the patients. 
The patients were divided into three diagnostic groups by clinical criteria: Acute 
pyelonephritis — fever > 38.0°C and flank pain and/or costo-vertebral angle 
tenderness with or without disturbed micturition; febrile UTI - fever > 38.0°C and 
frequency and/or dysuria in the absence of flank pain and/or costo-vertebral angle 
tenderness, and acute cystitis - frequency and/or dysuria, no flank pain or costo­
vertebral angle tenderness, and a body temperature < 38.0°C. All patients had at 
least 10s colony-forming units (CFU) of E. coli in pure growth per mL of freshly 
voided midstream urine (MSU) or indwelling bladder catheter urine (n=2). 
Prospective study (II, III, IV) 
A total of 114 patients attending the Department of Infectious Diseases with a 
presumptive diagnosis of febrile UTI were enrolled between March 1993 and 
January 1996 (Fig. 1). 
Informed consent to participate was obtained from all patients. The study protocol 




The patients were required to be 18 years of age or older, have fever > 38.0°C and 
at least one symptom or sign referable to the urinary tract (frequency, dysuria, 
flank pain or costo-vertebral angle tenderness). 
Non-inclusion criteria 
Indwelling urinary catheters, treatment with antibiotics during the preceding three 
days, known hypersensitivity to ciprofloxacin, renal impairment (estimated 
creatinine clearance < 2 0 mL/min or serum creatinine > 2 40 |imol/L), concomitant 
treatment with drugs that might interact with ciprofloxacin, such as theophylline 
and warfarin, or earlier inclusion in this study. 
A computer-generated randomisation list was used to allocate patients to either of 
the two treatment groups (IV). 
Definition of febrile UTI 
The patients had to fulfill the inclusion criteria and have a positive urine culture 
defined as > 104 CFU per mL urine [39], Among 114 patients randomised to the 
treatment trial (IV), 42 (37%) were withdrawn from efficacy analyses since they did 
not meet the criteria for evaluation (Table 1). However, 14 of these patients fulfilled 
the definition of febrile UTI and could thus participate in the other two studies (II, 
III). 
Patient characteristics 
Characteristics of study patients are shown in Table 2. 
Patients in the retrospective study (I) who were assigned a diagnosis of acute 
pyelonephritis or febrile UTI are here given a diagnosis of febrile UTI. 
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Table 1. Reasons for non-evaluation after randomisation (IV). 
Ciprofloxacin 500 mg b.i.d. 
2 weeks 4 weeks 
(n=19) (n=23) 
Not fulfilling inclusion criteria3 6 8 
Other diagnosis than febrile UTIb 3 3 
Negative initial urine culture 4 7 
Isolated pathogen resistant to ciprofloxacin 1 0 
No follow-up 2 3 
Premature discontinuation of treatment 
because of adverse event 
0 1 
Insertion of a permanent urinary 
catheter during treatment 
3 1 
a Treatment with other antibiotics (n=7) or with drugs that might interact with 
ciprofloxacin (n=4), hypersensitivity to ciprofloxacin (n=l), previous inclusion in 
the study (n=l) and inability to comply with the study protocol (n=l). 
b All with negative urine cultures. 
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Table 2. Characteristics of patients with febrile UTI. 
Retrospective study 
No. (%) Median (range) 
Prospective study 
No. (%) Median (range) 
No. of p atients 74 86 
Age (years) 61 (23-86) 63 (18-86) 
History of UTI 21/69 (30) 38 (44) 
History of febrile UTI 24 (28) 









Diabetes mellitus 10 (14) 6 ( 7 )  
Dysuria 44 (59) 66/83 (80) 
Frequency 54 (73) 73/83 (88) 
Flank pain and/or 
costo-vertebral angle 
tenderness 
41 (55) 31 (36) 
Prostatic tenderness 9/76 (12) 
Circumcision 4/82 (5) 
Temperature (°C) 74 39.0 (38.0-40.8) 86 39.5 (38.0-41.4) 
CRP (mg/L) 68 83 (6-280) 86 130 (9-420) 
ESR (mm/h) 66 38 (2-105) 82 30 (4-100) 
WBC (xl09/L) 38 13.7 (3.9-26.4) 85 13.2 (4.0-29.0) 
Pyuria 69/82 (84) 
Haematuria 81 (94) 
Positive nitrite test 45 (52) 
Positive blood 
cultures 
8/43 (19) 14/84 (17) 
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METHODS 
Retrospective study (I) 
Bacteriological procedures 
The E. coli strains had been stored in deep agar nutrient stabs at room 
temperature until analysed. 
The somatic (O), capsular (K) and flagellar (H) antigens were determined with 
antisera to 171 O, 74 K and 53 H antigens [40]. Capsular polysaccharides K1 and 
K5 were identified by specific phages [40]. Non-typeable strains were defined as 
ON, KN and HN, respectively. Strains that agglutinated in saline were designated 
spontaneously agglutinating (OR). Strains with no demonstrable capsule were 
denoted K-. Non-motile cultures were denoted H-. 
The occurrence of P fimbriae was assayed by a P-specific latex agglutination test 
(PF-test; Orion Diagnostica, Espoo, Finland) [41]. 
Alpha haemolysin production was assessed in nutrient agar with 5% washed sheep 
erythrocytes. A haemolytic zone larger than the overlying colony after overnight 
incubation was considered positive [42]. 
Aerobactin secretion was determined in a bioassay in which aerobactin-producing 
test strains promoted growth of the aerobactin-requiring E. coli strain LG1522 [43]. 
Prospective study (II, III, IV) 
Bacteriological procedures 
After collection, urine specimens were kept at 4°C until examined. The urine was 
cultured semiquantitatively on blood agar and Cysteine-Lactose-Electrolyte-
Deficient (CLED) agar plates under aerobic and also under anaerobic conditions 
using the calibrated loop technique [44], Urine samples containing more than two 
bacterial species were considered contaminated. 
Two sets of blood cultures obtained before treatment were incubated both 
aerobically and anaerobically. 
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All is olates were identified by standard methods [44], Antimicrobial susceptibility 
testing was done using the disk diffusion method [45], E. coli strains were stored in 
deep agar nutrient stabs at room temperature before 0:K:H serotyping and 
determination of virulence properties were done. 
Biochemical analyses 
C-reactive protein in serum (CRP), erythrocyte sedimentation rate (ESR), white 
blood cell count (WBC) and creatinine in serum were measured by standard 
methods. 
Ames Multistix®5 test strip (Bayer Diagnostics) was used for assessment of urinary 
nitrite, pyuria and haematuria. A reaction of trace or greater was considered 
positive. 
Prostate-specific antigen (PSA) was analysed using a monoclonal fluoro-
immunoassay (Delfia®, Wallac Oy, Turku, Finland). 
Creatinine clearance was estimated by the Cockcroft-Gault formula [46]. 
Urological investigations 
Transrectal ultrasound of the prostate (TRUS) was conducted using Bruel and 
Kjaer 3535 equipment with a 7 MHz 8551 multiplane probe. The prostate volume 
was calculated as the height x width x length x rt/6 [47], The width of the seminal 
vesicles was measured as the maximum antero-posterior diameter. 
Postvoid residual urine volume was measured by abdominal ultrasonography 
(transducer 8542, Bruel and Kjaer Medical, Naerum, Denmark). 
Uroflowmetiy, cysto-urethroscopy and imaging studies were performed by 
standard methods. 
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Assessment of treatment efficacy (IV) 
The clinical response was considered satisfactory if all symptoms related to the 
infection resolved during treatment. Persistent or worsened symptoms were 
designated as clinical failure. 
Bacteriological cure: eradication of the infecting strain with no recurrence of 
bacteriuria (<104 CFU/mL) during follow-up. 
Relapse: post-treatment bacteriuria with the same strain as that originally 
isolated. 
Reinfection: post-treatment bacteriuria with a strain different from that originally 
isolated. 
In case of E. coli infection, serotyping made it possible to differentiate between 
relapse and reinfection. 
In asymptomatic recurrences, bacteriuria was defined as > 105 CFU/mL of a single 
strain in two consecutive urine samples or > 105 CFU/mL in one sample together 
with a positive nitrite test. 
Statistical methods 
Papers I-IV 
Pitman's test [48] , Fisher's permutation test [48], or the Mann-Whitney U-test was 
used to compare differences in the distribution of data between groups. 
Proportions were compared by the chi-square test with Yates' correction or 
Fisher's exact test. Fisher's test for pair-wise comparisons [48] or Wilcoxon's 
signed-rank test was used for paired data. Correlations among variables were 
tested using Pitman's test. 
Two-tailed significance tests were used and P < 0.05 was considered to indicate 




To detect a 20% unit difference in bacteriological cure rate between the two 
treatment regimens, and assuming a cure rate of 95% at short-term follow-up of 
patients treated for 4 weeks, it was calculated that approximately 100 évaluable 
patients had to be enrolled in the trial. This was based on a 2-tailed chi-square test 
with a type I (a) error of 0.05 and a type II (ß ) error of 0.2. 
19 
Scheduled investigations (II, III, IV) 
At study entry 
Detailed clinical history 
Physical examination 
Blood specimens for 
Two sets of cultures 
Analyses of PSA, CRP, ESR, WBC and 
creatinine 
M SU sample for 
Dipstick urine analyses 
Culture 
Digital rectal examination 
Uroflowmetry 
Measurement of postvoid residual urine volume 
TRUS 
At 1. 3, 6 and 12 months 
Detailed clinical history 
Physical examination 
Blood specimens for analyses of 
PSA, CRP, ESR, WBC and creatinine 
MSU sample for 
Dipstick urine analyses 
Culture 
At 3 months 
Excretory urography 
Cysto-urethroscopy 
Digital rectal examination 
Uroflowmetry 




Serotypes and virulence properties of E. coli isolated from men with 
symptomatic UTI (I) 
Q:K:H serotypes 
The E. coli serotypes showed great diversity in all diagnostic groups. Fifty-eight 
different serotypes could be identified among the 88 strains examined. Eight 
strains belonged to serotype 018ac:K5:H-, while no other serotype was represented 
by more than three strains. 
Seventy-six strains (86%) had a typeable somatic antigen, representing 18 different 
O groups. Sixty-nine strains (78%) expressed somatic antigens belonging to 10 
common O antigen groups associated with acute pyelonephritis in women and 
children (Ol, 02, 04, 06, 07, 08, 015, 016, 018ac, and 075). A large proportion 
of the strains (26%) belonged to serogroup 06. 
UTI-related types of K antigen (Kl, K2, K3, K5, K12, K13, and K53) were expressed 
by 60% of the strains. Among isolates from patients with acute pyelonephritis and 
febrile UTI, 15 (20%) and 16 (22%) possessed Kl and K5 antigens, respectively, 
while 12 (16%) were non-encapsulated. 
Virulence properties 
There were no significant differences in the distribution of P fimbriae, haemolysin, 
or aerobactin between strains from patients with acute pyelonephritis and those 
with febrile UTI (Table 3). P fimbriae were expressed by 51% of the strains, while 
haemolytic activity and production of aerobactin could be demonstrated in 74% 
and 46%, respectively. The distribution of virulence properties was similar among 
isolates from men older and younger than 50 years of age. 
P fimbriae were primarily associated with 02, 04, 016 and 018ac compared with 
all other O antigen groups (81% vs 35%; P<0.001). Haemolytic activity was 
commonly associated with 04, 06, 016 and 018ac but was less often associated 
with other O antigen groups (87% vs 60%; P<0.01). 
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Table 3. Distribution of virulence properties of E. coli according to diagnosis 
in men with symptomatic UTI (%). 
Diagnosis No. of P fimbriae Haemolytic Aerobactin 
patients activity production 
Acute pyelonephritis 41 23 (56) 30 (73) 21 (51) 
Febrile UTIa 33 15 (45) 25 (76) 13 (39) 
Acute cystitis 14 5 (36) 7 (50) 6 (43) 
aWithout flank pain or costo-vertebral angle tenderness. 
Virulence versus host response 
In patients with acute pyelonephritis or febrile UTI, there were no significant 
differences in inflammatory activity whether the infection was caused by P 
fimbriated E. coli or not (Table 4). Nor were there any differences in this respect 
whether or not the strains produced haemolysin or aerobactin. 
Table 4. Host response to infection by E. coli with or without P fimbriae in patients 
with acute pyelonephritis or febrile UTI. Median (range). 
P fimbriae Temperature CRP ESR 
(°C) (mg/L) (mm/h) 
Pos 39.0 93 42 
(38.0-40.8) (6-238) (2-86) 00 CO II G
 
00 co il C
 n=35 
Neg 39.0 84 35 
(38.0-40.4) (11-280) (6-105) 
n=36 n=30 n=31 
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Bacteriological findings in the prospective study (II, III, IV) 
E. coli was the predominant pathogen and accounted for 78% of the urinary 
isolates (Table 5). Gram-positive bacteria which often occur as commensals in the 
urethral flora were isolated in 10% of cases, but not among those who were under 
57 years of age (n=30). Indeed, non-E. coli strains were only isolated from patients 
> 57 years old (n=56). E. coli of the same 0:K:H serotype were recovered from 
concurrent blood and urine samples. Patients with positive blood cultures were 
older than those with negative blood cultures (median age 72 years, range 48-84 vs 
61 years, range 18-86;P=0.02). 
Table 5. Bacteriological findings in 86 patients with febrile UTI. 
Urinary isolates Blood isolates" 
Escherichia colib 67 (78 %) 10 
Klebsiella pneumoniae 7 
Enterobacter aerogenes 1 1 
Enterobacter agglomerans 1 1 
Proteus mirabilis 1 1 
Enterococci 4 
Staphylococcus epidermidis 3 1 
Group B streptococci 2 
aBlood cultures were obtained from 84 patients. 
bIn one case together with Serratia marcescens. 
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Characteristics of E. coli strains 
A total of 55 of 67 E. coli strains have so far been examined for 0:K:H serotype, and 
production of haemolysin and aerobactin (unpublished data). The findings were 
comparable to those obtained in the retrospective study (I). Thus, 42 (76%) strains 
belonged to the 10 common O antigen groups and 14 (27%) strains belonged to 
serogroup 06. Among 40 (73%) encapsulated strains, 10 (25%) and eight (20%) 
possessed K1 and K5 antigens, respectively. Production of haemolysin and 
aerobactin was found in 39 (71%) and 19 (35%) of the isolates, respectively. 
Involvement of the prostate gland in men with febrile UTI (II) 
PSA levels 
The PSA levels peaked early during the acute infection (Table 6). The initial serum 
PSA was elevated (> 4 |ag/L) in 58 (83%) of 70 patients (Table 7). Despite a rapid 
decline in PSA after one month (P<0.001), 43% of the patients still had raised PSA 
levels (Fig 2). A further decrease in PSA could be demonstrated after 3, 6 and 12 
months. Interestingly, one patient (No. 51; Table 6) with disseminated prostate 
cancer who had raised baseline levels of PSA responded to the infection with a 
further increase in serum PSA. 
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Table 6. PSA levels (ng/L) in repeat serum samples during the first week of 
treatment. 
Patient Days after study entry 
No. 0 1 234567 
3 7.2 3.1 
12 11 14 9 
36 43 26 17 11 8.2 7.8 
51 130 280 230 130 
76 23 13 19 11 8.4 7.8 
77 23 11 9 
82 4.3 25 
95 3.2 2.6 
98 18 24 
101 58 51 47 
107 17 15 16 13 
The median time of fever before entry was 1 day (range 1-4 days). 
Table 7. Median serum PSA after an episode of febrile UTI. 
Months3 No. of Serum PSA (Mg/L) No. (%) of patients with 
patientsb Median Range serum PSA > 4 Mg/L 
0 70 14.0 
1 69 3.6 
3 55 2.9 
6 50 2.0 
12 41 1.5 
0.54-140 58 (83) 
0.43-21 30 (43) 
0.38-19 23 (42) 
0.37-20 16 (32) 
0.36-16 10 (24) 
aTime after an episode of febrile UTI. 
b Incomplete data from 29 patients who did not comply with all scheduled visits 
(n=10), underwent TURP (n=9), had recurrent febrile UTI (n=6) or biopsy-verified 
prostate cancer (n=2), or died (n=2) during follow-up. 
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Fig 2. Median serum PSA after an episode of febrile UTI. 
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Months 
Six patients had a recurrent febrile UTI during follow-up, five of whom could be 
analysed for PSA. After treatment of the initial infection, the PSA levels decreased 
in all but one patient, followed by a transient increase associated with the 
recurrence (Table 8). No patient with recurrent ABU (n=9) or lower urinaiy tract 
symptoms without fever (n=5) showed an increase in PSA. 
Table 8. Serum PSA levels (pg/L) in men with recurrent episodes of febrile UTI. 
Patient Months after the initial episode of febrile UTI. 
No. O 1 2 3 6 7 11 12 
1 4.6 2.7 23.0 a 3.8 3.5 
3 5.8 7.2 a 1.2 1.6 1.0 
12 33.0 3.9 1.8 11.0 a 
43b 1.4 1.2 9.6a 0.80 7.4 * 0.86 1.1 
55 19.0 1.3 2.1 1.5 35.0a 2.2 
a Recurrent febrile UTI. 
b Patient using clean intermittent self catheterisation. 
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PSA levels in patients with other febrile infectious diseases 
Sixteen men (median age 49 years, range 22-90) who were admitted with a 
temperature > 3 8.0° C, no clinical signs of UTI and a negative urine culture were 
included as controls. None had been treated with antibiotics during the preceding 
three days. The final diagnoses at discharge were pneumonia (n=5), influenza 
(n=4), other viral diseases (n=2), salmonellosis (n=2) and one each of endocarditis, 
malaria and streptococcal pharyngitis. The median PSA level at entry was 0.99 
Ug/L (range 0.40 - 2.7). 
Prostate volume 
Among 55 patients who had two ultrasound examinations of the prostate, at entry 
and after three months, a significant decrease in prostate volume was found 
[median (range) mL, 49 (14-104) vs 35 (15-91); P<0.001]. The prostate volume 
increased slightly in one patient, was unchanged in three patients, while 51 
patients had a reduction, which exceeded 10% in 46 cases (median 31%, range 11-
54). 
The seminal vesicles were measured twice in 40 patients. 
On the right side the maximum width was reduced by 14%, from a median (range) 
of 11.0 (3.0-20.0) mm to 9.4 (4.2-16.0) mm (P<0.001), and on the left side by 22 %, 
from 11.5 (4.0-18.0) mm to 9.0 (4.6-17.0) mm (P<0.001), at follow-up. 
Serum PSA and prostate volume 
A reduction of serum PSA by more than 25%, irrespective of the initial PSA level, 
and/or a decrease in prostate volume by more than 10% between the acute phase 
and follow-up after three months was taken as evidence of prostatic involvement of 
the infection. With these assumptions, 46 (94%) of 49 patients who completed both 
examinations had a concomitant infection of the prostate (Table 9). Of the 55 
patients who had two PSA measurements performed, 51 (93%) showed a reduction 
of PSA by > 2 5%, suggesting that serum PSA alone could be used as a marker of 
prostatic involvement. 
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The reductions of PSA and prostate volume were not significantly correlated to 
patient age, the magnitude of initial C-reactive protein levels, the presence of 
bacteraemia, whether the infection was first-time or recurrent, or whether it was 
caused by Gram-negative or Gram-positive bacteria. Nor were the results 
influenced by previous transurethral resection of the prostate (TURP). 
Table 9. Changes in serum PSA and prostate volume between the acute stage of 
infection and 3 months later in 49 men with febrile UTI. 
Reduction in serum PSA Reduction in prostate volume 
>10% <10% 
>25% 40 4 
<25% 2 3 
Prostate biopsy and TURP 
Five patients underwent TRUS-guided prostate needle biopsy, because of findings 
suggesting cancer on digital rectal examination or TRUS after 3 months, as did 9 of 
15 patients who had persistently elevated serum PSA (> 4 .0 mg/L) after 6 months. 
The reasons for not performing a biopsy were patient refusal in five cases, three of 
whom had normal PSA levels at 12 months, and TURP in one case. Microscopic 
evidence of prostate cancer was found in two patients with increased PSA levels 
(27, 21, 11,11 pg/L and 74, 20, 19, 20 Hg/L at entry and after 1, 3 and 6 months, 
respectively). None of the nine patients who underwent TURP had evidence of 
cancer in the resected tissue. 
Urinary tract investigation (III) 
Upper urinary tract 
Imaging studies were carried out by excretoiy urography (n=76), ultrasonography 
(n=4) or computed tomography (n=3). Abnormalities were disclosed in 19 patients, 
nine of whom had previously unrecognised lesions. The findings had clinical 
implications in only one patient, who eventually underwent surgical intervention 
because of renal calyceal stones. 
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Lower urinarv tract 
In five of 10 men with voiding difficulties from benign prostatic hyperplasia (BPH) 
and who subsequently underwent TURP, the findings were known before study 
entry (Table 10). A young man with a urethral stricture also had phimosis and a 
history of voiding difficulties. He experienced an early recurrence of febrile UTI 
caused by the same E. coli strain as that originally isolated. The stricture was 
diagnosed by cysto-urethroscopy and surgically corrected. Four patients had mild 
urethral strictures with no voiding difficulties, which were diagnosed and dilated or 
incised at cysto-urethroscopy after three months. 
Table 10. Lower urinary tract abnormalities in 83 men with febrile UTIa. 
Abnormality No. (%) of findingsb 
Infravesical obstruction from BPH requiring TURP 10 
Urethral stricture 5 
Bladder diverticulum 5 
Bladder stones 3 
Bladder cancer 1 
Phimosis 1 
Postvoid residual urine > 50 mLc 13 (22) 
Peak urinary flow rate < 10mL/sc 8 (15) 
a Diagnosed by cysto-urethroscopy (n=73), ultrasonographic measurement of 
postvoid residual (n=60) and uroflowmetry (n=52) at the follow-up after 3 months. 
b Forty-six abnormal findings in 35 patients. 
c Based on the best performance during the acute stage or at follow-up. 
Urological abnormalities in relation to bacteriological findings, host response and 
recurrent UTI 
There was no association between the bacteriological aetiology, the occurrence of 
positive blood cultures or the magnitude of fever and inflammatory response to 
infection and urological abnormalities leading to surgery. Fifteen (22%) of 67 
patients tested had haematuria as measured by dipstick analysis at follow-up 
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after one month. Three of four patients with stone disease and the one with 
bladder cancer had haematuria at short-term follow-up (Table 11). 
During the 1-year follow-up, 26 patients had 37 episodes of culture-confirmed 
recurrent UTI, 16 of which were symptomatic. Three of five patients with early 
recurrent symptomatic UTI within one month after the end of a ntibiotic treatment 
had an abnormality leading to surgery. All patients who had urological disorders 
that warranted surgical intervention were identified among those with a history of 
voiding difficulties, acute urinary retention, early recurrent symptomatic UTI or 
microscopic haematuria at the first post-treatment control. Thus, in this study 
only 20 (24%) of 85 men would have required both upper and lower urinary tract 
investigation to reveal such abnormalities. 
Table 11. Characteristics of 15 men with febrile UTI who had surgically correctable 
lesions that were previously unrecognised. 
No. of History Acute Haematuria8 Recurrent 
patients of voiding urinary symptomatic 
difficulties retention UTF> 
Intravesical obstruction 
from BPH requiring TURP 5 5 2 1 
Urethral stricture 5 1 1 1 
Bladder stones 3 3 2 1 
Renal calyceal stones 1 1 
Bladder cancer 1 1 1 
a As measured by dipstick analysis at follow-up after 1 month. 
b Within 1 month after the end of antibiotic treatment. 
Renal function in patients with scarred kidneys 
Twelve patients with a median (range) age of 73 (29-86) years had radiological 
signs of renal scars. They had an estimated creatinine clearance [median (range)] 
of 56 (22-125) mL/min at follow-up. Four of these patients, aged 73 - 86 years, 
had an estimated creatinine clearance of < 50 mL/min. 
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Ciprofloxacin for two or four weeks in men with febrile UTI (IV) 
A total of 72 patients randomly allocated to oral treatment with ciprofloxacin 
500 mg twice daily for two or four weeks were assessable for bacteriological and 
clinical efficacy. 
Signs and symptoms cleared in all patients during treatment. The median time to 
resolution of fever was 2 days (range 1-9). The cumulative bacteriological and 
clinical cure rates during the 1-year follow-up are shown in table 12. 
There was no significant difference in short-term bacteriological cure rate two 
weeks post-treatment between patients treated for two and four weeks (89% vs 
97%; 95% CI for difference in proportions, -4% to 19%), nor after one year (59% vs 
76%; 95% CI, -5% to 39%). The cumulative clinical cure rate after one year was 
72% and 82%, respectively (95% CI, -10% to 30%). 
The presence of urinaiy tract abnormalities did not influence the outcome, but two 
of four patients with early symptomatic recurrence had major disorders requiring 
surgery (severe urethral stricture with phimosis and bladder cancer). The results 
suggest that a 2-week course of ciprofloxacin 500 mg twice daily is adequate 
treatment for febrile UTI in men. 
Adverse events were seen in one of fo ur patients, were usually mild and occurred 
early during the course even among those assigned to the 4-week treatment. 
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Table 12. Cumulative cure rate (%). 
Ciprofloxacin 500 mg b.i.d. 
2 weeks 4 weeks 
(n=38) (n=34) 


















Recurrent UTI during follow-up 
Among 21 (32%) culture-verified recurrences after one year, there were eight 
relapses and 12 reinfections. The clinical recurrence pattern comprised ABU 
(n=10), lower urinary tract symptoms with bacteriuria (n=5) and another episode of 
febrile UTI (n=6). 
Most recurrences (67%) occurred within three months after the end of antibiotic 
treatment, with no significant differences between the 2- and 4-week ciprofloxacin 
regimens. 
Recurrent UTI tended to be more common among patients with a past history of 
UTI than in those without [13 (38%) of 34 vs 8 (21%) of 38; ns]. However, four of 
five patients who experienced multiple recurrences during follow-up had a history 




In the retrospective study (I), th e E. coli strains were mainly obtained from patients 
participating in controlled treatment trials of community-acquired symptomatic 
UTI. Accordingly, these patients were well-characterised. The strains studied were 
collected during a 10-year period, minimising the risk of selecting serotypes that 
predominate because of variations in occurrence with time. 
The prospectively studied patients (II, III, IV) were probably representative of men 
with community-acquired febrile UTI. Some of them had known urological 
abnormalities, such as prostatic hyperplasia, and recent instrumentation of the 
urinary tract predisposing to infection, while others had never experienced a 
previous UTI. 
The medical records of all males admitted to the Department of Infectious Diseases 
during the prospective part of the study and discharged with a final diagnosis of 
acute pyelonephritis or febrile UTI were reviewed. Twenty-five patients met the 
inclusion criteria but had for various reasons not been included in the study. They 
were comparable to study patients as regards age, severity of infection and 
bacteriological aetiology. 
Virulence of E. coli causing male UTI (I) 
The vast majority of symptomatic infections in men were caused by 0:K:H 
serotypes of E. coli commonly associated with acute pyelonephritis in women [20], 
Most strains were encapsulated (84%), which is consistent with the findings in 
women with acute pyelonephritis [20]. The capsule has been proposed to increase 
virulence by preventing opsonisation and phagocytosis [49]. The K1 and K5 
antigens were found in 42 % of the isolates, compared with 63% of isolates from 
women. These capsular antigens are thought to enhance E. coli virulence because 
of close structural resemblance to certain host structures [50, 51], thereby having 
a selective advantage by escaping host defences. 
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The proportion of P fimbriated E. coli was lower (51%) than that in women with 
uncomplicated acute pyelonephritis (80%), but comparable to that in women with 
complicated infections (50%) [20]. P fimbriae are considered to be an important 
virulence property since P fimbriated E. coli become resident and persist longer in 
the faecal flora than other E. coli strains [52], Furthermore, P fimbriae facilitate the 
spread of E. coli to the urinary tract by adhesion to mucosal surfaces and seem to 
be important for ascent of bacteria to the kidneys and invasion of the renal 
parenchyma in patients with normal urinary tracts [53]. 
There was an unexpectedly high proportion of strains that showed haemolytic 
activity (74%), which could also be confirmed in the prospective part of this study 
(71%). The finding could be ascribed to the frequent occurrence of E. coli strains of 
serogroup 06 (26% and 27%, respectively), which is known to be associated with 
haemolysin production [19, 54]. A similar high proportion of haemolytic strains 
(91% and 71%) was reported in two earlier small studies of men with symptomatic 
UTI comprising 11 and 14 E. coli strains, respectively [21, 22]. In contrast, 
expression of haemolysin was found in approximately 50% of strains from women 
with uncomplicated pyelonephritis [19, 20], 
Furthermore, in a study of 30 men with acute or chronic bacterial prostatitis, 22 
(73%) E. coli strains showed haemolytic activity and 16 (53%) possessed P fimbriae 
[55], Similarly, in a study from Japan, 107 (69%) E. coli strains from men with 
acute prostatitis were haemolytic [56]. 
Haemolysin may contribute to mucosal damage and tissue injury by its cytotoxic 
effects (57), thereby facilitating invasion by bacteria. Since 94% of the men with 
febrile UTI in the prospective part of this study had signs of prostatic involvement 
by the infection, it is tempting to speculate that haemolysin production offers 
bacteria a selective advantage to infect and/or persist in the prostate tissue. 
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Aerobactin, a siderophore which has the ability to compete with iron-binding 
proteins in the host, has been regarded as a virulence factor of uropathogenic E. 
coli since it occurrs in a large proportion of strains (73%) associated with 
pyelonephritis in women [19]. Again, in men with febrile UTI, aerobactin was 
expressed by E. coli strains in a lower frequency (46%). 
To conclude, E. coli strains from men with febrile UTI belonged to a variety of 0:K:H 
serotypes commonly encountered in women with acute pyelonephritis. The 
distribution of virulence properties, however, suggests different host-parasite 
relationships in the male and female urinary tracts, which may possibly be 
attributed to the role of the prostate gland in male UTI. 
Prostatic involvement in men with febrile UTI (II) 
At enrolment, nine (12%) of 76 patients with febrile UTI had a tender prostate on 
digital rectal examination, indicating a concomitant infection of the prostate gland. 
PSA is a serine protease which is produced by epithelial cells of the prostate gland 
and is secreted into the seminal fluid, where it liquefies the ejaculate [58]. Under 
normal conditions, only small amounts of PSA leak into the bloodstream. Increased 
serum concentrations of PSA are found in patients with prostate cancer [59], The 
tissue-specific property has made PSA a useful marker for the detection of prostate 
cancer but raised serum levels have also been demonstrated in men with benign 
prostatic hyperplasia [60, 61] or acute prostatitis [62]. It has been suggested that 
the release of PSA into the blood might be enhanced by increased vascular 
permeability associated with an inflammatoiy process in the prostate [63, 64], 
Among the prospectively studied men with febrile UTI, 83 % had increased serum 
PSA (>4 ng/L) in the acute stage of t he infection, suggesting prostatic involvement. 
Indeed, the serum concentrations were comparable to those found in patients with 
prostate cancer [65], in some cases exceeding 100 ng/L. After an intitial rapid 
decline in serum PSA, there was a protracted decrease which in some patients 
lasted for several months. Sixteen (32%) of 50 patients still had raised serum PSA 
after six months. The possibility of a prolonged increase in serum PSA after 
successful antibiotic treatment of febrile UTI should therefore be considered when 
PSA is used for the detection of prostate cancer. However, only two of n ine patients 
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with a sustained increase in serum PSA had microscopic evidence of prostate 
cancer at biopsy. It may thus be suggested that prostate biopsy should not be 
performed earlier than six months after an episode of febrile UTI, unless digital 
rectal examination or TRUS arouses strong suspicion of cancer. 
Furthermore, a second rise in serum PSA occurred in five patients who 
experienced recurrent episodes of febrile UTI during follow-up, but not among 
those who had recurrences without fever. 
Among patients who underwent TRUS, the prostate was commonly enlarged, 
containing intraglandular calcifications and hypoechogenic areas in the peripheral 
zone. Those who underwent two TRUS examinations, at study entry and after three 
months, showed a significant decrease in the prostate volume as well as in the 
width of the seminal vesicles. These findings strongly suggest the presence of an 
acute inflammatory process in the prostate which subsided after appropriate 
antimicrobial treatment. Such changes in prostate volume, although less 
pronounced, have previously been shown in patients treated for bacterial 
prostatitis [66]. 
The age-adjusted prostate volume after three months was comparable to that 
found in a study of healthy Swedish men [67], supporting the conclusion that the 
inflammation had resolved. The serum half-life of PSA has been estimated to 2.2 
days in patients undergoing radical prostatectomy [59], The slow decline in serum 
PSA found in some patients after treatment of febrile UTI, despite normalised 
prostate volume, is therefore hard to explain. Perhaps the epithelial cells of the 
prostate continue to produce or release PSA for some time after the inflammation 
has subsided. 
Assuming that a reduction in serum PSA by more than 25% and/or a decrease in 
prostate volume by more than 10% indicates prostatic engagement by the 
infection, a total of 94% of the patients examined had a concomitant infection of 
the prostate. 
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Urinarv tract investigation in men with febrile UTI (IUI 
Since UTI rarely occurs in adult men, it is generally considered that a symptomatic 
UTI in a man of any age should be regarded as a complicated infection that 
necessitates a thorough evaluation of the urinary tract, to exclude predisposing 
factors of clinical importance [1, 68]. In this study of unselected men with 
community-acquired febrile UTI, radiological examination of the upper urinary 
tract revealed relevant clinical abnormalities in only one patient, who had renal 
calyceal stones. This patient had no history of previous UTI or renal stone disease. 
Renal scars were found in 12 patients, most of whom were elderly. Four of these 
patients had an estimated creatinine clearance of < 50 mL/min. Assessment of 
renal function seems more relevant than the disclosure of a renal scar by imaging 
techniques. In all, 19 (23%) of 83 patients investigated had some abnormality. The 
findings were similar to those in a previous study of women with community-
acquired acute pyelonephritis [69]. 
In a retrospective study of 50 elderly men with recurrent bacteriuria, 11 (22%) had 
urological abnormalities detectable by excretory urography [70], which accords 
with the findings in the present study. In another study of 38 young male students 
with symptomatic UTI [18], 11 (29%) of those investigated had normal urinary 
tracts. It was concluded that routine urological evaluation seems unnecessary in 
young men. 
In the present study, lower urinary tract investigation disclosed a variety of 
abnormalities, some of which had clinical implications. Altogether, 15 of 85 
patients with febrile UTI had previously unrecognised lesions that were surgically 
corrected. They were all identified either by a history of voiding difficulties, acute 
urinary retention, early recurrent symptomatic UTI or microscopic haematuria at 
the first follow-up after treatment, except for four men with mild urethral strictures 
diagnosed at the scheduled cysto-urethroscopy. Only 20 (24%) of the 85 men 
would have required both upper and lower urinary tract investigation to reveal 
urological disorders that warranted surgical intervention. 
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Antibiotic treatment of febrile UTI in men (IV1 
This was the first study to compare different lengths of antibiotic treatment of 
febrile UTI in men. A 2 -week course of ciprofloxacin 500 mg twice daily seemed to 
give similar bacteriological and clinical cure rates as a 4-week course. The 
cumulative cure rates were comparable during follow-up for one year. The results 
should be interpreted with some caution, however, since the wide confidence 
interval for differences in cure rates between the study groups will reduce the 
power of the trial. The high cure rates at short-term follow-up are consistent with 
those obtained with a fluoroquinolone in women with acute pyelonephritis [37, 39]. 
The cumulative bacteriological cure rates were also comparable to those obtained 
in men with chronic bacterial prostatitis who received a 4-week course of 
ciprofloxacin 500 mg twice daily and were followed-up for nine months [71], 
Since more than 90% of the men had a concomitant infection of the prostate, as 
measured by transient increases in serum PSA and prostate volume (II), t he goal is 
not only to sterilise the urine but also to eradicate the prostatic infection. 
Antimicrobials reaching free concentrations in prostatic tissue and prostatic fluid 
that exceed the minimum inhibitory concentrations of most of the causative 
bacteria should therefore be chosen for treatment of UTI in men. The 
fluoroquinolones, like ciprofloxacin, have such favourable pharmacokinetic 
properties and antibacterial spectra [72, 73]. Trimethoprim also yields good 
concentrations in the prostate and is an alternative to fluoroquinolones provided 
the causative bacteria are fully sensitive to the drug. In contrast, the use of beta-
lactam antibiotics should be discouraged because of the low concentrations 
attained by these drugs in the prostate [32, 73]. Actually, beta-lactam antibiotics 
seem to result in lower cure rates in men with febrile UTI [37, 74], 
Chronic bacterial prostatitis is considered to be the main cause of recurrent UTI in 
men [12, 25]. The high relapse rate after treatment has been attributed to the 
failure to eradicate bacteria from the prostate [12, 25]. 
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Bacteria may be protected in biofilms adjacent to calculi in prostatic tissue, as well 
as in areas of scarring [75, 76], Bacteria embedded in biofilms are quiescent, with 
low metabolic activity and slow growth, which diminishes their susceptibility to 
various antimicrobial drugs. Accordingly, it is extremely difficult to eradicate 
bacteria in the prostate even with appropriate antimicrobial treatment. Long 
treatment courses do not seem to be of any benefit since antimicrobials rarely cure 
chronic bacterial prostatitis. 
In the present study, relapses constituted 40% of the bacteriological recurrences 
after one year, suggesting an underlying chronic infection of the prostate. Sixty per 
cent of the recurrences were reinfections with a new bacterial strain. This may be 
due to instrumentation of the urinaiy tract, since new strains are easily introduced 
in conjunction with such procedures [12]. Neither a history of previous UTI, nor 
the presence of urological abnormalities was associated with an increased risk of 
recurrent UTI. On an individual basis, the natural history of UTI in men is quite 
unpredictable. Why exacerbations of chronic bacterial prostatitis result in various 
clinical manifestations of UTI with the same bacterial strain is unknown. 
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CONCLUSIONS 
• E. coli strains from men with febrile UTI belonged to a variety of serotypes 
commonly encountered in women with acute pyelonephritis. There was a higher 
proportion of haemolytic strains but a lower frequency of P fimbriated and 
aerobactin-producing strains than previously found in women, suggesting 
different host-parasite relationships in the male and female urinaiy tract. 
• The prostate was coinfected in over 90% of men with febrile UTI, as measured 
by transient increases in serum PSA and/or the prostate volume. 
• Routine radiological examination of the upper urinaiy tract seems dispensable 
in men with febrile UTI. Abnormalities of clinical importance were mainly 
disclosed by lower urinaiy tract investigation. 
• All patients who had lesions that required surgical intervention could be 
identified either by a history of voiding difficulties, acute urinaiy retention, 
microscopic haematuria at short-term follow-up or early recurrent symptomatic 
UTI. 
• There were no significant differences in cure rates between patients treated with 
ciprofloxacin for two and four weeks. A 2-week course of ciprofloxacin seems to 
be adequate for febrile UTI in men. 
• Most episodes of recurrent UTI occurred within three months after the end of 
treatment. Neither a history of previous UTI nor the presence of urological 
abnormalities was associated with an increased risk of recurrent UTI. 
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